XML 23 R7.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
CASH FLOWS – OPERATING ACTIVITIES    
Net loss $ (36,199) $ (17,727)
Adjustments required to reconcile net loss to cash flows used in operating activities    
Depreciation 2,922 1,803
Stock-based compensation 2,091 1,848
Gain from early lease termination (2,949)
Finance expense (income), net 256 (435)
Revaluation of contingent consideration (77) (78)
Income from change in fair value of warrants (6,111) (26,458)
Private Placement Warrants issuance cost 732
Changes in contract liability (1,976)
Loss from sale and disposal of fixed assets, net 205 221
Goodwill impairment 801
IPR&D impairment 11,842 3,237
Other long-lived asset impairment 1,653 4,046
Changes in operating assets and liabilities:    
Other current assets 2,243 842
Trade account payables 1,238 (3,167)
Other account payables (3,430) (984)
Net change in operating leases (74) 316
Net cash used in operating activities (26,390) (36,979)
CASH FLOWS – INVESTING ACTIVITIES    
Cash and restricted cash acquired from the APT acquisition 663
Purchase of property and equipment (2) (30)
Proceeds from sale of property and equipment 110 82
Net cash provided by investing activities 108 715
CASH FLOWS – FINANCING ACTIVITIES    
Issuance of Common Stock under February 2025 SPA 996
February 2025 SPA issuance costs (118)
Issuance of Common Warrants under February 2025 SPA 4,531
Issuance of Common Stock under Inducement Letter Agreements 6,473
Pre-Funded Warrants exercise 2 6
Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs 1,305 19
Repayment of long-term debt (10,747)
Issuance of Private Placement Warrants under March 2024 PIPE 28,745
Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE 21,269
March 2024 PIPE issuance costs (918)
Net cash provided by financing activities 13,189 38,374
Increase (decrease) in cash and cash equivalents and restricted cash (13,093) 2,110
Effect of exchange rate changes on cash and cash equivalents and restricted cash 73 1
Cash and cash equivalents and restricted cash at the beginning of the year 17,975 15,864
Cash and cash equivalents and restricted cash at the end of the year 4,955 17,975
Cash and cash equivalents 4,360 16,856
Restricted cash 595 1,119
Total cash and cash equivalents and restricted cash 4,955 17,975
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for interest 20 1,442
Taxes paid in Israel 7 13
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:    
Lease liability and Operating lease right-of-use asset remeasurement 2,487
Derecognition of right-of-use asset as a result of operating lease termination 1,799
Derecognition of lease liability as a result of operating lease termination 4,902
Property and equipment purchases included in accounts payable 1
Issuance cost from March 2024 PIPE 1,273
Issuance of Common Stock under the APT acquisition 3,041
Issuance of Redeemable Convertible Preferred Shares under the APT acquisition 12,610
Issuance of Merger Warrants under the APT acquisition 200
Redeemable Convertible Preferred Shares conversion into shares of Common Stock $ 28 $ 13,774